Seminar in Biotechnology

04/23/2014

Eugene Galanter, Ph.D.

Distinguished Emeritus Professor of Psychology and Quondam Director

Psychophysics Laboratory, Columbia University

The Two-Dimensional Mind: Mind as Representation

Biotechnology Speakers Fund
04/09/2014

Matt Owens

Executive Director

Harlem Biospace

Representatives

Exsponge, Inc.

Symbiotic Health

04/02/2014

Tejdeep Bawa

Associate Consultant

IMS Consulting Group

The Cost of a Cure

03/26/2014

Jenna Foger

Director of Life Sciences and Strategic Projects

Alexandria Real Estate Equities

Beyond the Bench: Career Alternatives in the Biotech Biz

03/12/2014

Lital Asher-Dotan

Senior Product Marketing Manager

Rapid7 LLC

Life After M.A. in Biotech: Things That I Learnt, Things You Need to Know

03/05/2014

Sathapana (Sam) Kongsamut

President, Rudder Serendip LLC

Interim CEO, Biochron Therapeutics

From Big Pharma to Startup Biotech

02/26/2014

Catherine Kopil

Associate Director, Research Programs

The Michael J. Fox Foundation for Parkinson's Research

Derisking the Therapeutic Pipeline- The Michael J. Fox Foundation's Strategy to Funding Parkinson's Disease Research

05/01/2013

Thomas Wegman

President

BioSpecifics Technologies Corp

Innovators in the Development and Commercialization of Injectable Collagenase

04/17/2013

Rob Fishman

Partner

Sandler Training

The Science of Effective Communication- Your Formula for Success

04/10/2013

Anthony Sanfiz

Scientist

Immunology Department at Merck

Beta-3 Adrenergic Receptor Agonists and the Treatment of Overactive Bladder

04/03/2013

Mahiuddin Ahmed

Senior Research Scientist, Department of Pediatrics

Memorial Sloan-Kettering Cancer Center

Antibody Engineering for Pediatric and Adult Cancer Therapy

03/27/2013

Donna Gardner

Professor

Middlesex Community College

You Want to Teach Where? Using an Ivy League Education to Create a Community of Scholars

03/13/2013

Scott D. Locke

Partner and Chair

Intellectual Property and Life Sciences Practice Areas

Dorf & Nelson LLP

Navigating Intellectual Property Issues in the Life Science Industry: Leveraging Ingenuity to Generate Profit

03/06/2013

Howard R. Levin

President and Chief Scientific Officer

Coridea, LLC

Medical Device Development in the Real World: Good, Bad, and Ugly

02/25/2013

Biotechnology Symposium

presented by students from Columbia University

and Institut de Mananagement des Industries de la Santé

02/20/2013

Ilyas Washington

Columbia University Medical Center

Ophthalmology

From Bench to Almost Bedside: an ongoing story of drug development

04/25/2012

Sofia Caamano
Sr. Clinical Scientist
Forest Research Institute
Kristina Dabovic

Clinical Trial Leader

Novartis

Out of the Lab and Into Man: An Overview of Early Drug Development

04/18/2012

Paul Sheiffele
President

inGenious Targeting Laboratory
25 Years of Mouse Genetics

04/11/2012

Thomas J. Dodd and Hal Woodrow
Patent Law Department

Johnson & Johnson
Patent Law and Pharmaceutical Exclusivity

03/21/2012

Harish Radhakrishna, Ph.D.
Director, Project Management and Exploratory Research

Chromocell Corporation
Convergence of Biotechnology with Chemosensory Biology

03/07/2012

Lily Khidr, Ph.D.
Publisher

Elsevier
Demystifying the Publishing Enterprise

02/29/2012

Christopher Brooks
Associate Director, R&D,

Stemline Therapeutics, Inc.
Developing Therapeutic Antibodies: Novel Ideas and Creative Approaches

02/15/2012 Konstantine Drakonakis
Director, LaunchCapital, LLC
Early Stage Venture Investing in Medtech
04/20/2011 Kevin O’Driscoll, Ph.D.
Medical Director, SuperNova Productions
Principal, O’Driscoll Consulting, LLC
The Persistent Paradigm of Sir Percivall Pott
04/13/2011

Matthew Rogers, Ph.D.
Director, Cellular Biology, R&D
Firmenich, Inc.
Biotechnological Approaches to Consumer Product Development

03/30/2011

David Jacobs, J.D. M.A.
Senior Counsel, USP Law and Promotion Compliance Department
Iram Ahmad, Pharm. D.
Post-doctoral Fellow, Oncology Medical Affairs
Bristol-Myers Squibb
Follow-on Biologics

03/23/2011 Alberto Spinazzi, M.D.
Senior Vice President, Group Medical and Regulatory Affairs
Bracco Diagnostics Inc.
Development of Medical Imaging Drugs
03/09/2011 Michal Silverberg, MBA, M.A.
Director Business Development and New Product Commercialization
Novo Nordisk
Novo Nordisk- Business Development, what does it mean?
02/09/2011

Lan Hu, Ph.D.
Founder, Synergion Biotech, Inc
CEO, NeoMatrix Formulations
From Bench to Business

02/02/2011

Amy S. Jenner
Vice President of Sales, Psychiatry and Ophthalmics

Pfizer
Pharmaceutical Promotion in 2011 – A Sales’ Professional Perspective

04/21/2010

Edwin Grimsley

Case Coordinator

The Innocence Project

The Legal Implications of DNA Technology

04/07/2010

Greg Miller

Executive Director

OurMed.org

OurMed, An Innovative Approach to Non-Commercial and Credible Healthcare Information

03/31/2010

Gary Zammit, PhD

Principal, CEO

Clinilabs, Inc.

How Medicines Are Made: A Real Life Perspective On Clinical Drug Development

03/24/2010

Jacob S. Sherkow, MA, JD

Associate

Gibson Dunn

The U.S. Supreme Court's Impact on Biotechnology

03/03/2010

Bruce Schiamberg, PhD

Principal

Schiamberg Group

How to Evaluate the Commercial Potential of New Technologies: introduction to life sciences consulting and business development

02/03/2010

Randall K. Ribaudo, PhD

President, CEO

Human Workflows, LLC

Science Careers in Industry - What's Out There and How to Get Ready

01/27/2010

David B. Klein

Managing Director and Head of Global Recruiting

Paramount BioSciences

Career Paths and the Business of Biotechnology

04/29/2009

Nicholas Wade

Author and Reporter
The New York Times
The Faith Instinct – How religion evolved and why it endures

04/15/2009

Noah Weisleder, PhD

Co-founder and Chief Scientific Officer
TRIM-edicine, Inc.
Protein Therapeutics in Regenerative Medicine

04/08/2009

Brendan Rauw, MBA

Portfolio Director
Science and Technology Ventures, Columbia University
University-Industry Alliances in Life Sciences

04/01/2009

Imtiaz Mawji, PhD

Consultant
Datamonitor Healthcare Consulting
The Role of Concurrent design in Guiding Strategic Decisions in the Pharmaceutical Industry

03/25/2009

Daniel Yarosh

Senior Vice President
Basic Science Research, The Estee Lauder Companies
Biotechnology: Going to Market

03/11/2009

Alan Morrison, JD

Partner
Cohen Pontani Lieberman & Pavane, LLP
Understanding the Biotechnology Patent

03/04/2009

Daniel Ferrara, MA Biotechnology

Criminalist
Office of the Chief Medical Examiner, NY City
Forensic DNA Testing: Science serving Justice

02/18/2009

Robert Tillman, PhD

Director, Science Alliance
The New York Academy of Sciences
The Roles of Non-profits in Advancing Science and Innovation

04/23/2008

Jamie Li, PhD

Director, Urology/Gynecology R/D
Boston Scientific
The Practical Part of Biotechnology

04/16/2008

Michael A. Davitz, MD, JD

Partner
Axinn, Veltrop & Harkrider LLP
The Role of Intellectual Property in the Pharmaceutical and Biotechnology Environment

04/09/2008

Aseem Anand, MA Biotechnology

Clinical Trial Coordinator, MSKCC, and

Founder, BioTrak
Organizational Issues in Biotech

04/02/2008

David Best, MD, MBA, and Michael Banks, MD
President and Vice President

MDea, Inc.
Careers in Medical Communication and Big Pharma

03/26/2008

Alan E. Smith, PhD

Senior Vice President, Research, Chief Scientific Officer
Genzyme Corp.
Therapies for Genetic Diseases

03/12/2008

David Sable, MD

Fund Manager
Special Situations Life Sciences Fund
Investing in Biotechnology: Inside a Life Sciences Hedge Fund

03/05/2008

Michael Rice

Senior Consultant
Defined Health
Cardiovascular Franchises: Too Much Risk in Prevention?

02/27/2008

Greg Homison, PhD

Director of Research and Technical Services
Department of Biological Sciences
Infrastructure:  From the Mechanical to the Interpersonal

02/20/2008

Angelos M. Stergiou, MD

VP Product Development, Medical Affairs & Clinical Research
Accentia Biopharmaceuticals
Treating and Curing Patients, Clinical Research and Development

02/13/2008

Daijin Kim, MBA

Associate Director, Healthcare Informatics
Pfizer Human Health
Challenges & Opportunities in the Pharmaceutical Industry

04/25/2007

Ross Grossman, PhD, MBA

VP, Human Resources
Regeneron Pharmaceuticals, Inc.
Organizational Issues in Biotech

04/11/2007

Ivica Labuda

Founder and President
Biokeys for Flavors, LLC
Biotechnology Role in Flavor Industry

04/04/2007

Kelly Wines, MA Biotechnology

Associate
Fitzpatrick, Cella, Harper & Scinto
Intellectual Property: Where Technology Meets the Law

03/28/2007

Jerry Di Salvo

Distinguished Senior Research Associate, Department of Immunology
Merck Research Laboratories
A View from the Bench:  Basic Research and Drug Development

03/21/2007

Melanie Rolli, MD

Director, Brand Safety Leader, Integrated Medical Safety
Novartis Pharmaceuticals Corporation
From Bench to Bedside: The Process and the People that Turn an Idea into a Drug

03/07/2007

Vivien Marx

Science Writer
The Art of Describing Science to the World

02/28/2007

Chau Cheng, PhD

Associate Director, Investor Relations and Business Analysis
ImmunoMedics
Investor Relations in the Biotech sector. What is unique about it?

02/14/2007

Nelson Scharadin, MA Biotechnology

Investment Banker

Healthcare Investment Banking, Oppenheimer & Co

Falling forward in the business of Biotechnology

02/07/2007

Heather Butts

Regulatory Specialist

Institutional Review Board, Columbia University
Bringing it all together: issues in research ethics, history and review

04/26/2006

Gary Shangold, MD

President & Managing Member

Convivotech, LLC.
Creating Your Own Career in the Life Sciences

04/19/2006

Ron Guido and Alan McEmber

Directors, Worldwide Regulatory Strategy
Pfizer
Pitfall Avoidance: Regulatory Affairs as Tactician in Biotechnology Product Development

04/05/2006

Eugene Trogan, PhD

Biotechnology Analyst
Ursus Capital Management
Biotech and the Savvy Investor: How to Stay with the Good and part with the Bad

03/29/2006

Thierry Teil, MD

Executive Director
The Medicines Company
Pharma and Biotech Industry: Overview & Opportunities for Biology Graduates

03/22/2006

Steve Dinh, Sc.D.

Vice President, Research and Technology Development
Emisphere
Oral Delivery of Protein Therapeutic Molecules

03/08/2006

Eliene Augenbraun, DO, PhD

CEO and President
ScienCentral, Inc.
Bite Size Biotech – how most Americans learn about science

03/01/2006

Philip Braginsky, JD

Of Counsel
Sills Cummis Epstein and Gross
The Commercial Realm of Patents

02/15/2006

Holly Hilton, PhD

Research Informatics, Genetics and Genomics
Hoffmann-La Roche Inc.
The Role of Functional Genomics in Drug Discovery

02/10/2006

Marie Teil, MD

Director, Clinical Trials Office
Mount Sinai School of Medicine
Drug Approval Process -from an FDA perspective or from a pharma point of view

02/08/2006

Jeff Yablon

Principal
Yablon Management Consulting/PharmaScan Clinical Trials, LLC.
Introduction to Clinical Development & Biotech Management Concepts

02/01/2006

Lata Jayaraman, PhD

Senior Research Investigator
Bristol-Myers Squibb
Choosing a Career in the Bio-Pharmaceutical Industry

04/27/2005

William Fair, MA

VP, Healthcare & Biosciences

New York City Economic Development Corp.
Commercial Bioscience in New York
04/20/2005

Josh Xiao, PhD

Sr. Scientist
Amgen San Francisco
High Throughput Screening in the Functional Genomics Era

04/13/2005

Ivan Oransky, MD

Deputy Editor
The Scientist
Biotechnology and the Media

04/06/2005

Costa Papastephanou, PhD

President and COO
Ortec International
The Anatomy of a Biotech Company

03/30/2005

Linda Armstrong, MD

Medical Director
Pfizer
Assessing Drug Safety: From Bench to Blockbuster

03/23/2005

Mark Kay, MD, PhD

Director, Human Gene Therapy Program
Stanford University
Gene Transfer Strategies for Treating Hemophilia and Viral Hepatitis

03/09/2005

Allen Fienberg, PhD

Founder & VP, Business Development
Intra-Cellular Therapies
Reflections on the Transition from Academia to Corporate Life

03/02/2005

Michael Yamin, PhD

Director, Technology Development
Warren Pharmaceuticals, Inc.
Tissue Protective Cytokines from Discovery to Development

02/23/2005

Jeff Margolis

President
Aurora Capital LLC
Start-up and Early Stage Biotechnology Companies: Translating Science into Products

02/16/2005

Charles Ryan, PhD, JD

Executive Director, Chief Patent Counsel
Forest Laboratories, Inc.
The Role of Intellectual Property in Pharmaceutical Drug Development

04/21/2004

Eelco A. Slagter, MS

Director of Science and Technology
AMDeC Foundation, inc.
Developments in the Biosciences: An Integrative Approach

04/14/2004

Ramana Sonty, MBBS, PhD

Senior Director, Worldwide Development
Pfizer
Integrated R&D/Commercial Cross-Functional Approaches to Strategy, Portfolio and Risk

04/07/2004

Rene Baston, MA and Matthew McCooe, MBA

Associate Directors
Columbia University Science and Technology Ventures
Technology Transfer - Making an Impact

03/31/2004

Sundeep Bhan

President and CEO
Medsite, Inc.
Exploring Entrepreneurial Opportunities in Biotechnology

03/24/2004

Nicholas Giorgio, PhD

Senior Director of Protein Sciences
ImClone Systems, Inc.
A Brief History of Erbitux, from the Lab Bench to Approval and Beyond

03/10/2004

Melanie Rolli, MD

Associate Director, Clinical Research
Novartis Pharmaceuticals
From Bench to Bedside: The Process and the People that Turn an Idea into a Drug

03/03/2004

Mary Morry, PhD, JD

Senior Attorney, Intellectual Property Litigation
Merck & Co.
Patents and Practical Tips for Obtaining and Using Them

02/25/2004

Ilya Trakht, D. Sc.

Chief Research Consultant
Acceptys
Totally Human Antibodies: from Bench Science to Biotech Business

02/11/2004

David Sudolsky, MBA

Principal
Sudco Consulting
Adventures of a Serial Biotech Entrepreneur

02/04/2004

David Weinstein, PhD, MD

President and Chief Scientific Officer
GliaMed Inc.
Biology-based Drug Discovery in the Nervous System

01/28/2004

Charles Jennings, PhD

Executive Editor
Nature Research Journals
The Role of Journals in the Communication of Science

04/23/2003

Louis J. Capezzuto, JD, MA Biotechnology

Patent Law Department
Johnson & Johnson
Biotechnology Patents 101- The Basics

04/16/2003

Uwe Scherf, PhD

Director, R & D
Gene Logic
Whole Genome Expression Profiling: Generating and Utilizing High Quality Data

04/09/2003

Nezih Cereb, MD

Executive VP and co-founder
Histogenetics, Inc.
Clinical Implications of Polymorphism of the Human MHC (Major Histocompatibility Complex) Genes - -Industrialization of Molecular Tissue Typing

04/02/2003

Don O’Sullivan, PhD  

Senior Account Executive
Euro RSCG Life NRP
Communicating Biotechnology-the value of public and investor relations in the life sciences industry

03/26/2003

Rene Baston, MA and Matthew McCooe, MBA

Associate Directors
Columbia University Science and Technology Ventures
Technology Transfer from Academia

03/12/2003

Tina Lopingo, PhD 

Director, Technology and Business Development
New York Biotechnology Association

New York’s Biotechnology Landscape
03/05/2003

Julie Kan, PhD 

Senior Research Investigator
OSI Pharmaceuticals
The ‘omics’ World for Small Molecule Cancer Drug Discovery

02/26/2003

Bharat Mehta, PhD

VP Manufacturing Operations
Genta, Inc.
Regulatory Requirements in Pharmaceutical Manufacturing with Focus on Critical Utilities and BSE/TSE-Viral Safety

02/19/2003

Andrew Marshall, PhD

Editor
Nature Biotechnology
The Vision of Genomics and the Reality in Drug Development

02/12/2003

Timothy Howe, MBA

Partner
Collinson Howe & Lennox Medical Partners
Venture Capital in the Biotechnology Space

02/05/2003

Rudolph Spangler, PhD

Senior Research Associate
Rockefeller University
Designing an Efficient High Throughput Gene Expression Technology

01/29/2003

M. Timothy Cooke, PhD MBA

CEO
Mojave Therapeutics
Creating Value: Business Models in Biotechnology

05/01/2002

Anthony J. Russo, PhD

CEO and General Manager
Noonan/ Russo
Public Relationship in Biotechnology

04/24/2002

Hillel Cohen, PhD

Director, Drug Regulatory Affairs
Novartis Pharmaceutical Corporation
The Role of Regulatory Affairs in Development of Biopharmaceuticals.

04/17/2002

Kenneth H. Sonnenfeld, PhD

Partner
Morgan and Finnegan
The Swinging Pendulum of Biotechnology Patent Law: What’s patentable and What’s Not

04/10/2002 Robert Crowl, PhD
Novartis Pharmaceuticals Corporation
Genomics and Drug Target Discovery Facing the Challenge of Osteoarthritis
04/03/2002

Frank Carrigan, PhD, Beth S. Kauderer, PhD, JD, Mathew McCooe, MBA

Director and Associate Directors
Columbia University Science and Technology Ventures
Risk in the Capital Transformation Process

03/27/2002

George D. Yancopoulos, MD, PhD

President, Executive VP and CSO
Regeneron Pharmaceuticals
Merging Biology with Drug Discovery in Obesity, Inflammation, Angiogenesis, Muscle Disease & Other Setting

03/13/2002 OSI Pharmaceuticals
Field trip
03/06/2002

Young Whan Park, PhD

Research Fellow
Merck Research Laboratories
Current Techniques in High Throughput Screening for Drug Discovery Processes

02/27/2002

Jean Denaro, MA

Project Manager
Pfizer Pharmaceuticals
Clinical Research: Methods and Opportunities

02/20/2002

Harmen Bussemaker, PhD 

Professor
Columbia University
Computational Analysis of Genome Sequences and DNA Microarray Data

02/13/2002

Alex Elbrecht, PhD

Research Fellow
Merck Research Laboratories
Compound Characterization Using Gene Microarrays

02/06/2002

Ron Cohen, MD

President, CEO, Founder and Director
Acorda Therapeutics
So You Want to Start a Biotech Company, Hmmm?

11/28/2001

Jules T. Mitchel, PhD

President
Target Health, Inc.
Principles of Drug Development: a case study in AIDS

11/19/2001 Raymond S. Fersko, JD
Mints, Levin, Cohn, Ferris, Glowsky & Pepeo, P.C.
Commercializing Biotechnology
10/01/2001

Meirav Chovav, MA, MBA

Managing Director
Credit Suisse First Boston
Biotech, A Business Built on Science

04/25/2001

Shubha Govind, PhD

Professor
City College, City University of New York,

Drug Development Using Flies and Model Organisms
04/18/2001

Conrad Gilliam, PhD

Professor
Columbia Genome Center
Identification of Genetic Loci of Human Diseases

04/11/2001 Bernie Yurke, PhD
Lucent Technologies
Assembling Nanostructures and Nanomotors out of DNA
04/04/2001 Rene Hen, PhD Professor
Columbia University Department of Pharmacology
Animal Models for Diseases
03/28/2001 Robert Pearlman, Esq.
Intellectual Property Causes
Patenting
03/21/2001

Stuart Fischer, PhD

Research Scientist
Columbia Genome Center
High Through-put Physical Mapping

03/07/2001 Juergen Hammer, PhD
Hoffmann-La Roche Inc.
Gene Chips and Applications
02/28/2001 Victor Lin, PhD
Columbia University Irvin Cancer Center
Transgenic Mice Facilities
02/21/2001

James Russo, PhD

Research Scientist
Columbia University Columbia Genome Center
The Human Genome Project, Genome Sequencing, and Disease Gene Discovery

02/14/2001

Chris Adams

Founder and President
Mosaic Technologies
Entrepreneurship in Biotech Industry

02/07/2001

Eric Schon, PhD

Professor
Columbia University Department of Genetics and Development
Molecular Genetics of Human Mitochondrial Disease

01/31/2001

Cy Stein, MD

Professor
Columbia University Department of Medicine
Theory and Practice of the Antisense Biotechnology

01/24/2001

Donald Landry, MD

Professor
Columbia University Department of Medicine
Anti-cocaine Catalytic Antibodies

01/17/2001

Arthur Bank, MD

Professor
Columbia University Department of Medicine
On the Road to Hematopoietic Stem Cell Gene therapy